Such in vivo noninvasive NIR-II molecular imaging of CD8+ T cells and PD1 markers in tumor could complement ex vivo biopsy-based diagnostic techniques, such as immunofluorescence (IF) or immunohistochemistry (IHC). The gene discussed is CD8A; the disease is neoplasm.